<DOC>
	<DOCNO>NCT01811706</DOCNO>
	<brief_summary>Investigators expect improvement walk speed steadiness take Dalfampridine , thereby improve activity daily live enhance social occupational function patient spinocerebellar ataxia .</brief_summary>
	<brief_title>Dalfampridine Gait Spinocerebellar Ataxias</brief_title>
	<detailed_description>Twenty spinocerebellar ataxia patient randomize receive either Dalfampridine placebo total period 10 week . After enter study , patient return every 2 week evaluation . After four week , intervention stop patient enter 2-week wash period take drug . Then , patient give opposite treatment ( Dalfampridine placebo ) `` crossover '' study perform another 4 week . Investigators expect improvement walk speed steadiness take Dalfampridine , thereby improve activity daily live enhance social occupational function .</detailed_description>
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Spinocerebellar Ataxias</mesh_term>
	<mesh_term>Spinocerebellar Degenerations</mesh_term>
	<mesh_term>Machado-Joseph Disease</mesh_term>
	<mesh_term>4-Aminopyridine</mesh_term>
	<criteria>Individuals age 18 year old . Individuals provide inform consent Genetic confirm definite spinocerebellar ataxia ( SCA ) Able complete two trial time 25foot walk screen Patients severe ataxia unable ambulate . Any orthopedic condition would affect motor performance . Patients secondary ataxia general medical disorder Individuals major psychiatric disorder prevents compliance History epilepsy Patients active drug alcohol use dependence would interfere adherence study requirement Inability unwillingness subject legal guardian/representative give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>